- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01205074
¹³C-Methacetin Breath Test (MBT) Methodology Study
Several factors will be tested to see if they have an influence on the methacetin breath test results. Each one of the factors has been raised as a possible source of distortion of the MBT result.
I. Variability between same tests on same subject MBT. Repeatability will be tested in both healthy individuals and patients with chronic liver disease.
II. COPD - Chronic obstructive pulmonary disease is a leading cause of death worldwide, and can potentially have an effect on the MBT since the breath test is based on CO2 production and these subjects may have abnormal CO2 production.
III. Smoking- 13C Methacetin is metabolized by healthy hepatocytes reflecting hepatic microsomal function of CYP1A2, and smoking may cause induction of CYP1A2. Furthermore, internal preliminary data has shown signs that there is an influence of smoking on the MBT ranges.
IV. Age- Empirical data on several hundred subjects with chronic liver disease has shown that age is a significant factor in determining the probability of disease severity and preliminary data in normal subjects have shown changes in MBT with age.. Therefore, the effect of age has to be elucidated in an orderly fashion.
V. CYP450 1A2 Inhibitors- Several drugs and food items inhibit CYP450 1A2 and may affect the MBT.
VI. Alcohol - Alcohol ingestion leads to induction of hepatic CYP and at a later stage to inhibition due to liver damage. Acute alcohol ingestion may therefore effect MBT results.
VII. Beta-blockers - beta blocker are affecting portal hypertension and may affect hepatic blood flow and thereby the outcome of the methacetin breath test.
Study Overview
Status
Conditions
Study Type
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Liver Unit Hadassah Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion Criteria - General
- Adult subjects with 18 years of age or older
- Women of childbearing potential must have a negative serum or urinary hCG pregnancy test within 7 days prior to enrollment. During the study these women must use 2 methods of contraception.
- Subject has given written informed consent, prior to any study related procedure not part of the subject's normal medical care, with the understanding that consent may be withdrawn at any time without prejudice to future medical care.
Exclusion Criteria - General
- Severe heart, pulmonary or renal disease.
- Patient has previous surgical bypass surgery for morbid obesity
- Patient has extensive small bowel resection
- Any major surgery in the past 3 months.
- Patient is a recipient of any organ transplant
- Pregnant or breastfeeding women.
- Patient allergic to acetaminophen
- Patients who are taking hepatotoxic drugs
- Patient, based on the opinion of the investigator, should not be enrolled into this study.
- Patients unable or unwilling to sign informed consent
- Patients that are participating in other clinical trials evaluating experimental treatments or procedures or have participated in a clinical trial in the past 3 months.
Exclusion Criteria (Day of MBT-general)
- Patient has not fasted for 8 hours.
- Patient has smoked on the day of the test.
- Patient that has taken drugs that can interfere with methacetin metabolism: fluvoxamine, amiodarone, ciprofloxacin, cimetidine, rifampin, carbamazepine within the last 24 hours.
- Patient has taken Tylenol or any other acetaminophen related medications within the past 24 hours.
- Patients that received any new medication in the last 48 hours.
- Patients that still suffer from any previous clinical intervention (e.g. biopsy)
- Have not consumed alcohol 24 hours prior the MBT and not consume on a regular basis more than 40gr for male and 20gr for female per day.
Inclusion Criteria (Repeatability):
Healthy Subjects:
- No known liver disease
- Non smokers
- BMI =20-25 kg/m2
- Normal liver enzymes (ALT < 40 U/L for men, < 30 U/L for women)
- Not taking any medications
- No known on-going chronic medical conditions (apart from allergy or orthopaedic conditions not requiring chronic therapy).
- Normal abdominal ultrasound (US)
Cirrhotics:
- Diagnosis of cirrhosis by liver biopsy
- Or strong suspicion of cirrhosis by accepted criteria for the clinical diagnosis of cirrhosis (e.g. peripheral edema or varices, palpable hard left lobe of the liver, small right lobe span or palpable splenomegaly), and/or radiological evidence of cirrhosis (by abdominal sonography, computer assisted axial tomography, or magnetic resonance imaging, showing a nodular liver and/or portosystemic collaterals with portal vein patency and/or ascites and/or splenomegaly, and/or colloid shift on a colloid-isotope liver-spleen scan), and/or laboratory variables (platelets <100,000/mm3, albumin< 3.5g/dL, or INR >1.3)
Chronic Liver Patient (non cirrhotic):
Patient who has been diagnosed with chronic liver disease for more than 6 months.
Inclusion Criteria (COPD):
- No known liver disease
- BMI 20- 25 kg/m2
- Normal liver enzymes (ALT < 40 U/L for men, < 30 U/L for women)
- Patients with a COPD exacerbation with elevated PCO2 levels (> 50 mmHg)
- Without clinically overt right heart failure
- Ceased smoking for at least one month
- No other overt clinical dysfunction of major organ system
Inclusion criteria (Smoker):
Smokers:
- No known liver disease
- Active smoker of at least 10 cigarettes/day (stable number of cigarettes during past month - not currently trying to quit).
- BMI 20- 25 kg/m2
- Normal liver enzymes (ALT < 40 U/L for men, < 30 U/L for women)
- Not taking any medications
- No known chronic medical conditions
Inclusion criteria (CYP450 1A2 inhibitors):
Healthy Subjects:
- No known liver disease
- Non smokers
- BMI 20- 25 kg/m2
- Normal liver enzymes (ALT < 40 U/L for men, < 30 U/L for women)
- Not taking any medications
- No known chronic medical conditions (allergy or orthopaedic condition not requiring chronic therapy allowed).
- Normal abdominal US
Cirrhotic subjects:
- Diagnosis of cirrhosis by liver biopsy
- Or strong suspicion of cirrhosis by accepted criteria for the clinical diagnosis of cirrhosis (e.g. peripheral edema or varices, palpable hard left lobe of the liver, small right lobe span or palpable splenomegaly), and/or radiological evidence of cirrhosis (by abdominal sonography, computer assisted axial tomography, or magnetic resonance imaging, showing a nodular liver and/or portosystemic collaterals with portal vein patency and/or ascites and/or splenomegaly, and/or colloid shift on a colloid-isotope liver-spleen scan), and/or laboratory variables (platelets <100,000/mm3, albumin< 3.5g/dL, or INR >1.3)
- Not receiving medication which is metabolized by CYP450 1A2
Inclusion criteria (Beta Blockers):
- Diagnosis of cirrhosis (by liver biopsy or clinical diagnosis):
Strong suspicion of cirrhosis by accepted criteria for the clinical diagnosis of cirrhosis (e.g. peripheral edema or varices, palpable hard left lobe of the liver, small right lobe span or palpable splenomegaly), and/or radiological evidence of cirrhosis (by abdominal sonography, computer assisted axial tomography, or magnetic resonance imaging, showing a nodular liver and/or portosystemic collaterals with portal vein patency and/or ascites and/or splenomegaly, and/or colloid shift on a colloid-isotope liver-spleen scan), and/or laboratory variables (platelets <100,000/mm3, albumin< 3.5g/dL, or INR >1.3)
- Naive to Beta Blockers - with a clinical indication for initiating therapy (eg. esophageal varices, portal hypertensive gastropathy)
- Resting pulse > 60 beats per minute
- Non smoker
Inclusion criteria (Alcohol):
- No known liver disease
- Non smokers
- BMI 20- 25 kg/m2
- Normal liver enzymes (ALT < 40 U/L for men, < 30 U/L for women)
- Not taking any medications
- No known chronic medical conditions. (Allergy or orthopaedic condition not requiring chronic therapy allowed).
- Normal abdominal US
Exclusion Criteria:
General
- Severe heart, pulmonary or renal disease.
- Patient has previous surgical bypass surgery for morbid obesity
- Patient has extensive small bowel resection
- Any major surgery in the past 3 months.
- Patient is a recipient of any organ transplant
- Pregnant or breastfeeding women.
- Patient allergic to acetaminophen
- Patients who are taking hepatotoxic drugs
- Patient, based on the opinion of the investigator, should not be enrolled into this study.
- Patients unable or unwilling to sign informed consent
- Patients that are participating in other clinical trials evaluating experimental treatments or procedures or have participated in a clinical trial in the past 3 months.
Exclusion Criteria (Day of MBT-general)
- Patient has not fasted for 8 hours.
- Patient has smoked on the day of the test.
- Patient that has taken drugs that can interfere with methacetin metabolism: fluvoxamine, amiodarone, ciprofloxacin, cimetidine, rifampin, carbamazepine within the last 24 hours.
- Patient has taken Tylenol or any other acetaminophen related medications within the past 24 hours.
- Patients that received any new medication in the last 48 hours.
- Patients that still suffer from any previous clinical intervention (e.g. -
- Have not consumed alcohol 24 hours prior the MBT and not consume on a regular basis more than 40gr for male and 20gr for female per day.
Study Plan
How is the study designed?
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: COPD
|
|
Experimental: Repeatability
|
|
Experimental: Smokers
|
|
Experimental: CYP450 1A2 Inhibitors
|
|
Experimental: Cirrhosis Beta Blockers
|
|
Experimental: Alcohol
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Liver Diseases
- Fibrosis
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Central Nervous System Depressants
- Propranolol
- Ethanol
- Adrenergic beta-Antagonists
Other Study ID Numbers
- METH-EX-610- HMO - CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
University Health Network, TorontoUnknown
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
RenJi HospitalNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Institute of Liver and Biliary Sciences, IndiaRecruiting
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
Clinical Trials on 13C Methacetin Breath Test
-
Hadassah Medical OrganizationWithdrawnChronic Hepatitis BIsrael
-
Meridian Bioscience, Inc.CompletedNon-Alcoholic SteatohepatitisUnited States, France, Belgium, United Kingdom
-
Virginia Commonwealth UniversityOridionCompletedFatty Liver | CirrhosisUnited States
-
Meridian Bioscience, Inc.Conatus PharmaceuticalsCompletedCirrhosis | Portal Hypertension | NASH - Nonalcoholic SteatohepatitisFrance
-
University Hospital Birmingham NHS Foundation TrustPancreatic Cancer UKRecruitingPancreatic Exocrine InsufficiencyUnited Kingdom
-
Meridian Bioscience, Inc.Conatus PharmaceuticalsTerminatedDecompensated CirrhosisUnited States
-
Northwestern UniversityTerminatedDilated Cardiomyopathy | Tricuspid AtresiaUnited States
-
Meridian Bioscience, Inc.Bristol-Myers SquibbCompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
Meridian Bioscience, Inc.CompletedPatients With Compensated Liver CirrhosisUnited States, France, Switzerland, Spain
-
Universitaire Ziekenhuizen KU LeuvenCompletedHealthy | Gastric EmptyingBelgium